ATE215124T1 - Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen - Google Patents
Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungenInfo
- Publication number
- ATE215124T1 ATE215124T1 AT94921762T AT94921762T ATE215124T1 AT E215124 T1 ATE215124 T1 AT E215124T1 AT 94921762 T AT94921762 T AT 94921762T AT 94921762 T AT94921762 T AT 94921762T AT E215124 T1 ATE215124 T1 AT E215124T1
- Authority
- AT
- Austria
- Prior art keywords
- tetc
- vaccine compositions
- fusion protein
- fusion proteins
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1088—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB1993/001617 WO1994003615A1 (en) | 1992-07-31 | 1993-07-30 | Expression of recombinant fusion proteins in attenuated bacteria |
GB9401787A GB9401787D0 (en) | 1994-01-31 | 1994-01-31 | Vaccine compositions |
PCT/GB1994/001647 WO1995004151A2 (en) | 1993-07-30 | 1994-07-29 | Vaccine compositions containing recombinant tetc-fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE215124T1 true ATE215124T1 (de) | 2002-04-15 |
Family
ID=26302349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94921762T ATE215124T1 (de) | 1993-07-30 | 1994-07-29 | Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0712442B1 (de) |
JP (1) | JPH09500540A (de) |
AT (1) | ATE215124T1 (de) |
AU (1) | AU7235794A (de) |
CA (1) | CA2168459C (de) |
DE (1) | DE69430246T2 (de) |
WO (1) | WO1995004151A2 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5132851B2 (ja) * | 1997-08-05 | 2013-01-30 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用 |
US7923216B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
US7923015B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
EP1049712B1 (de) * | 1997-08-14 | 2007-01-24 | Institut Pasteur | Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren |
GB9720033D0 (en) * | 1997-09-19 | 1997-11-19 | Medeva Plc | Hepatitis B virus polypeptides |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
GB9916363D0 (en) * | 1999-07-13 | 1999-09-15 | Univ Bristol | Methods of suppressing cell growth |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1356820A1 (de) * | 2002-04-26 | 2003-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
KR101206544B1 (ko) | 2003-06-23 | 2012-11-30 | 박스터 헬쓰케어 에스.에이. | 백신용 담체 단백질 |
ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
PT2182983E (pt) | 2007-07-27 | 2014-09-01 | Janssen Alzheimer Immunotherap | Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
DK2788021T3 (en) | 2011-12-09 | 2017-04-10 | Bavarian Nordic As | POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68917126T2 (de) * | 1988-02-01 | 1995-02-02 | Praxis Biolog Inc | T-zellen-epitope als träger für einen konjugierten impfstoff. |
CA2031468A1 (en) * | 1989-12-08 | 1991-06-09 | Mitchell S. Gross | Malaria vaccine |
FR2656626B1 (fr) * | 1989-12-29 | 1994-08-12 | Pasteur Institut | Fragment peptidique comprenant une sequence issue de la proteine 28 kda de schistosoma mansoni et compositions vaccinantes et/ou therapeutiques comprenant ledit fragment. |
EP0574466B1 (de) * | 1991-03-05 | 1999-05-19 | The Wellcome Foundation Limited | Expression rekombinanter proteine in attenuierten bakterien |
WO1993008290A1 (en) * | 1991-10-16 | 1993-04-29 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
KR950702635A (ko) * | 1992-07-31 | 1995-07-29 | 크리스틴 헬렌 수덴 | 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria) |
-
1994
- 1994-07-29 EP EP94921762A patent/EP0712442B1/de not_active Expired - Lifetime
- 1994-07-29 WO PCT/GB1994/001647 patent/WO1995004151A2/en not_active Application Discontinuation
- 1994-07-29 AT AT94921762T patent/ATE215124T1/de not_active IP Right Cessation
- 1994-07-29 DE DE69430246T patent/DE69430246T2/de not_active Expired - Fee Related
- 1994-07-29 AU AU72357/94A patent/AU7235794A/en not_active Abandoned
- 1994-07-29 CA CA002168459A patent/CA2168459C/en not_active Expired - Fee Related
- 1994-07-29 JP JP7505668A patent/JPH09500540A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU7235794A (en) | 1995-02-28 |
WO1995004151A3 (en) | 1995-03-16 |
DE69430246T2 (de) | 2002-12-12 |
EP0712442A1 (de) | 1996-05-22 |
DE69430246D1 (de) | 2002-05-02 |
CA2168459C (en) | 2002-10-01 |
EP0712442B1 (de) | 2002-03-27 |
WO1995004151A2 (en) | 1995-02-09 |
CA2168459A1 (en) | 1995-02-09 |
JPH09500540A (ja) | 1997-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE215124T1 (de) | Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen | |
DK0574466T3 (da) | Udtrykkelse af rekombinante proteiner i svækkede bakterier | |
EP0722461A4 (de) | Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird | |
HUP0001650A2 (hu) | Javított expressziós vektorok | |
YU193887A (en) | PROCESS FOR OBTAINING APOLYPOPROTEINE "Al" | |
GB2295394A (en) | Vaccine Compositions | |
HU9501832D0 (en) | Improved vaccine for immunisation aga inst tbe virus infections as well as method for preparing them | |
KR970700770A (ko) | Htra-프로모터를 사용하여 독성이 약화된 박테리아내에서 이종 단백질을 발현시키는 방법(expression of heterologous proteins in attenuated bacteria using the htra-promoters) | |
ATE174963T1 (de) | Klonierung und expression eines rhoptry- assoziierten proteins aus p. falciparum | |
DK1241186T3 (da) | Humant vækststandsende specifikt gen-6 (gas-6) og nukleinsyrer kodende derfor | |
DK1328621T3 (da) | 13245, en ny human proteinkinase af den myotoniske dystrofitype og anvendelser deraf | |
DK1241251T3 (da) | Humant prostasin-lignende protein og nukleinsyrer kodende for samme | |
DK1241184T3 (da) | Humant synaptogyrin-lignende protein og nukleinsyrer kodende for dette |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |